Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
• Hospira (NYSE:HSP) reported Q1 EPS of $0.93, well ahead of the Zacks Consensus Estimate of $0.78 per share. Revenues for the quarter fell less by than a percent to $1.0 billion, topping the Zacks Consensus Estimate of $941.0 million
• Ford (NYSE:F) reported Q1 EPS of $0.61, beating the Zacks Consensus Estimate of $0.50 per share. Revenues for the quarter rose 17.8% year-over-year to $33.1 billion, higher than the Zacks Consensus Estimate of $30.188 billion
• Lockheed Martin Corp (NYSE:LMT) reported Q1 EPS of $1.55, above the Zacks Consensus Estimate for $1.51 per share. Revenues for the quarter increased 2.9% year-over-year to $10.63 billion, slightly lower than the Zacks Consensus Estimate of $10.644 billion
• Bearings and specialty steel manufacturer The Timken Co. (NYSE:TKR) raised its full year 2011 EPS guidance to between $3.80 and $4.10, from prior guidance of $3.30 to $3.60
• Share prices of biotechnology firm Endocyte, Inc.’s (NASDAQ:ECYT) rose 32.18% after the company said it was requesting European Union approval to market its treatment for ovarian cancer
• Morgan Joseph analysts upgraded shares of Central European Media Enterprises Ltd. (NASDAQ: CETV) from “Hold to "Buy rating with a target price of $25.00
• Bank of America Merrill Lynch upgraded Ingersoll-Rand (NYSE: IR) to "Buy" from “Neutral rating with a price target of $61.00 per share on the stock
• Analysts at Piper Jaffrey upgraded Johnson Controls, Inc. (NYSE: JCI) to "Overweight" from “Neutral rating with a price target of $47.00 per share up from $46.00
• Analysts at JPMorgan Chase & Co. upgraded Mission West Properties, Inc. (NASDAQ: MSW) to "Neutral" from an “Underweight rating with a target price of $7.00 raised from $6.00
• C.H. Robinson Worldwide (NASDAQ:CHRW) reported Q1 EPS of $0.59, slightly lower than the Zacks Consensus Estimate of $0.60 per share. Revenues for the quarter rose 14% year-over-year to $2.36 billion, ahead of the Zacks Consensus Estimate of $2.293 billion
• Becton Dickinson (NYSE:BDX) reported Q1 EPS of $1.38, ahead of the Zacks Consensus Estimate of $1.30 per share. Revenues for the quarter rose 7% year-over-year to $1.92 billion, above the Zacks Consensus Estimate of $1.856 billion
Get the full Analyst Report on HSP - FREE
Get the full Analyst Report on F - FREE
Get the full Analyst Report on LMT - FREE
Get the full Snapshot Report on TKR - FREE
Get the full Snapshot Report on ECYT - FREE
Get the full Snapshot Report on CETV - FREE
Get the full Snapshot Report on IR - FREE
Get the full Analyst Report on JCI - FREE
Get the full Analyst Report on CHRW - FREE
Get the full Analyst Report on BDX - FREE